Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Uncertainty surrounds semaglutide availability as supply challenges and regulatory discussions dominate headlines. However, compounded versions remain a viable option for weight management when prescribed through licensed healthcare providers. PlexusDx continues offering compounded semaglutide injection through verified 503A compounding pharmacies, ensuring patients have consistent access to this medication.

Understanding the Difference Between Brand and Compounded Semaglutide

Ozempic and Wegovy represent brand-name semaglutide manufactured by Novo Nordisk. These FDA-approved versions face intermittent supply disruptions due to manufacturing capacity and unexpected demand surges. Compounded semaglutide, by contrast, is produced by licensed 503A compounding pharmacies following FDA guidelines for prescription medications. The active ingredient remains identical, but the formulation process and source differ significantly from branded products.

Many patients confuse inventory challenges with product discontinuation. Recent semaglutide shortages primarily affected brand-name versions, not compounded alternatives. Licensed compounding pharmacies maintain their own manufacturing operations and ingredient sourcing, allowing them to operate independently from brand-name supply chains. This distinction matters for patients seeking reliable, long-term access to GLP-1 therapy without facing repeated delays.

Current Regulatory Status of Compounded GLP-1 Medications

The FDA regulates compounding pharmacies under section 503A of the Food, Drug, and Cosmetic Act. These facilities must comply with strict quality standards, sterility requirements, and ingredient verification protocols. Unlike brand-name drugs, compounded medications cannot claim FDA approval, but they operate under established regulatory authority when produced by licensed pharmacies. PlexusDx partners exclusively with 503A facilities that meet these compliance requirements.

Recent FDA communications have focused on preventing unlicensed sellers and fraudulent products, not restricting legitimate compounding. Regulatory scrutiny targets counterfeit GLP-1 products sold through unverified online channels, not medications dispensed by licensed compounding pharmacies with valid prescriptions. Patients using PlexusDx receive prescriptions filled through regulated facilities, protecting them from unproven or dangerous alternatives.

Why PlexusDx Compounded Semaglutide Remains Accessible

PlexusDx sources semaglutide injection from licensed 503A compounding pharmacies across the United States, avoiding dependence on brand-name supply chains. This approach provides patients with consistent availability regardless of Novo Nordisk manufacturing constraints. Starting at $149 per month, compounded semaglutide through PlexusDx remains affordable and accessible in all 50 states without requiring insurance coverage. Your dose may need to go up. Your price won't—patients maintain flat monthly pricing regardless of dose adjustments.

The compounding model allows greater flexibility in meeting patient needs. Licensed pharmacies can adjust formulations and work with prescribing providers to optimize therapy based on individual responses. PlexusDx combines this access with the Precision Peptide Genetic Test, a $99 add-on that maps 14 metabolic pathways and 49 peptides to identify which GLP-1 approach may work best for each patient's genetic profile.

Alternatives and Backup Options in PlexusDx Medication Portfolio

PlexusDx offers multiple GLP-1 options beyond compounded semaglutide injection, reducing reliance on any single product. Oral semaglutide starts at $249 per month, providing an alternative route of administration for patients who prefer non-injection therapy. Compounded tirzepatide injection ($249/month) and oral tirzepatide ($279/month) represent dual-action GLP-1 receptor agonist and GIP receptor agonist combinations, offering different metabolic mechanisms than semaglutide alone.

The GLP-Squared Injection ($249/month) combines semaglutide and tirzepatide in a single compounded formulation, creating a hybrid protocol for patients who may benefit from dual-peptide action. PlexusDx also offers the Microdose GLP-1 Protocol at $129 per month for patients beginning therapy or preferring lower initial dosing. This portfolio depth ensures patients have backup options if any single medication becomes temporarily unavailable, and all are produced through licensed compounding channels.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide actually being removed from the market?

No. Brand-name semaglutide (Ozempic, Wegovy) experienced supply constraints, but compounded versions from licensed 503A pharmacies remain available. PlexusDx continues offering compounded semaglutide injection at $149 per month across all 50 states with no insurance requirement.

How is compounded semaglutide different from Ozempic or Wegovy?

Compounded semaglutide is produced by licensed 503A pharmacies following FDA regulations, while Ozempic and Wegovy are brand-name versions manufactured by Novo Nordisk. The active ingredient is the same, but compounded versions avoid brand-name supply chain disruptions and typically cost less.

Is compounded semaglutide FDA-approved?

Compounded semaglutide cannot claim FDA approval as a brand-name drug. However, it is produced under FDA regulatory authority (503A compounding regulations) by licensed pharmacies meeting strict quality and sterility standards. PlexusDx sources exclusively from compliant facilities.

What if compounded semaglutide becomes unavailable—what are my backup options?

PlexusDx offers oral semaglutide, compounded tirzepatide (injection and oral), GLP-Squared combination injections, and the Microdose GLP-1 Protocol. This portfolio ensures patients have alternative therapies if any single medication faces temporary delays. All products are produced through licensed compounding pharmacies.

How does the Precision Peptide Genetic Test help me choose between semaglutide and other GLP-1 options?

PlexusDx's Precision Peptide Genetic Test ($99 add-on) analyzes key variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 to map 14 metabolic pathways. These insights help identify whether semaglutide, tirzepatide, or dual-peptide protocols align with your individual genetic predispositions for optimal response.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves